A Trial of Observed Long-acting, Anti-HIV Treatment With a Monoclonal CCR5 Antibody (PRO 140) as an Adjunct to a New, Optimized, Oral Antiretroviral Regimen in HIV-infected Injection Drug Users With Viral Rebound and Documented Poor Adherence

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:

18 Years and older (Adult, Senior)

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

No

Criteria

Key Inclusion Criteria:

Only R5 virus

HIV-1 RNA > 1,000 copies/mL but < 100,000 copies/mL

CD4+ lymphocyte counts > 100 cells/μL

Non-prescription recreational drug use within the previous 6 months

Key Exclusion Criteria:

Females who are pregnant (positive blood test), lactating, or breastfeeding, or who plan to become pregnant during the study

Prior use of any CCR5 entry inhibitors

History of any acquired immune deficiency syndrome (AIDS)-defining illness